Median LCS (internal name) / eyonis LCS (trade name) (1.0)
Overview
Median Technologies’ eyonis LCS (Lung Cancer Screening) is an AI/ML-powered Software as a Medical Device (SaMD) designed to aid in the detection and diagnosis of lung cancer in screening programs. It helps clinicians detect lung parenchymal nodules on low-dose CT (LDCT) scans and characterize them as probably benign, suspicious, or very suspicious, supporting early cancer diagnosis, patient risk stratification, and improved clinical management. The tool aims to address the challenges of false positives and false negatives that can hamper existing lung cancer screening programs. eyonis LCS is the first AI-based tool to combine computer-aided detection and diagnosis directly within the diagnostic care pathway of LDCT lung cancer screening. It provides both nodule detection capabilities and a nodule-specific malignancy score to support clinical decision-making.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI/ML-powered computer-aided detection (CADe) and diagnosis (CADx) for lung cancer screening
- Detects and characterizes lung parenchymal nodules on LDCT scans
- Provides nodule-specific malignancy score and Likelihood of Malignancy (LOM%) from 1% to 93%
- Reduces false positives by 68% and false negatives by 66% compared to unaided radiologists
- Achieves 93.3% sensitivity and 92.4% specificity
- Offers 99.9% Negative Predictive Value (NPV)
- Generates DICOM file result reports, compatible with PACS
- Flexible deployment: cloud-based or institution local hosting
- Integrates with existing workflows and PACS
- Supports patient risk stratification and improved clinical management
Use Cases
- Early detection and diagnosis of lung cancer in screening programs
- Reducing unnecessary follow-up procedures and patient anxiety
- Improving diagnostic confidence and screening efficiency for radiologists
- Supporting clinical decision-making from nodule identification through patient management
- Scaling lung cancer screening programs with enhanced accuracy and efficiency
- Addressing radiology capacity constraints and workforce shortages
Details
| Category | Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | Cloud-based or institution local hosting. |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pulmonology, Radiology |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2026-02-06 | K251474 510(k) | Median LCS (internal name) / eyonis LCS (trade name) (1.0) |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Median LCS (internal name) / eyonis LCS (trade name) (1.0)
Videos
Product demos, reviews, and walkthroughs for Median LCS (internal name) / eyonis LCS (trade name) (1.0).
No FAQs available yet for this tool.




